<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04074122</url>
  </required_header>
  <id_info>
    <org_study_id>70856</org_study_id>
    <nct_id>NCT04074122</nct_id>
  </id_info>
  <brief_title>Electromechanical Profiling of the Long-QT Syndrome (LQTS)</brief_title>
  <acronym>EMLoQ</acronym>
  <official_title>Electromechanical Profiling of Arrhythmogenic Substrates and Triggers in the Long-QT Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High-resolution, non-invasive electromechanical mapping in genotyped long-QT syndrome
      patients and healthy controls at baseline and during smart provocation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using simultaneous ECG-imaging, speckle-tracking analysis and tissue-phase mapping with MRI
      we will assess electromechanical dispersion at rest. Regional electromechanical elasticity
      will be investigated during adenosine and epinephrine, isoprenaline infusions and is
      postulated to increase sudden cardiac death risk prediction in the individual patient.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in regional electromechanical dispersion between LQTS patients and controls</measure>
    <time_frame>At day of investigation</time_frame>
    <description>Electromechanical dispersion in milliseconds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in regional electromechanical dispersion between symptomatic and asymptomatic LQTS patients</measure>
    <time_frame>At day of investigation</time_frame>
    <description>Electromechanical dispersion in milliseconds</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of electromechanical dispersion between LQTS type 1, 2, and 3.</measure>
    <time_frame>At day of investigation</time_frame>
    <description>Electromechanical dispersion in milliseconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relation between global electromechanical window vs regional electromechanical dispersion in LQTS</measure>
    <time_frame>At day of investigation</time_frame>
    <description>Electromechanical dispersion in milliseconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between mechanical dispersion using TPM-MRI and cine-MRI</measure>
    <time_frame>At day of investigation</time_frame>
    <description>Time-to-diastolic peak in milliseconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between mechanical dispersion using TPM-MRI and speckle-tracking echocardiography</measure>
    <time_frame>At day of investigation</time_frame>
    <description>Time-to-peak in milliseconds</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Long QT Syndrome</condition>
  <condition>Sudden Cardiac Death</condition>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Symptomatic LQTS patients</arm_group_label>
    <description>Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic LQTS patients</arm_group_label>
    <description>Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Adenosine and epinephrine, isoprenaline provocation</intervention_name>
    <description>High-resolution electromechanical mapping at baseline and after provocative measures.</description>
    <arm_group_label>Asymptomatic LQTS patients</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Symptomatic LQTS patients</arm_group_label>
    <other_name>ECG-imaging</other_name>
    <other_name>Tissue-phase mapping with MRI.</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Potential study subjects will be selected from the Cardiogenetic or Cardiac Outpatient
        Clinic or during their in-hospital stay.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        LQTS group (Group 1):

          -  Diagnosis of LQTS according to the ESC guidelines.

          -  Genetic testing either already performed or consent to genetic testing (at least 5
             major LQTS-related genes tested: KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2).

        Control group (Group 2):

        âž¢ Control subjects with structurally normal hearts.

        Exclusion Criteria:

          -  Pregnancy, nursing or planning to become pregnant.

          -  Known allergy or strong reaction to skin electrodes or contrast agent.

          -  Inability to give informed consent.

          -  Presence of metal objects in or attached to the body.

          -  Dialysis.

          -  Cardiomyopathy.

          -  Second-degree heart block or higher degrees of block.

          -  Sick sinus syndrome.

          -  Asthma.

          -  Chronic obstructive pulmonary disease.

          -  Left-main coronary artery disease.

          -  Unstable coronary artery disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Based on self-representation.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Volders, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht UMC+</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel ter Bekke, MD, PhD</last_name>
    <phone>+31433877095</phone>
    <email>rachel.ter.bekke@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Volders, MD, PhD</last_name>
    <phone>+31433877093</phone>
    <email>p.volders@maastrichtuniversity.nl</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Haugaa KH, Edvardsen T, Leren TP, Gran JM, Smiseth OA, Amlie JP. Left ventricular mechanical dispersion by tissue Doppler imaging: a novel approach for identifying high-risk individuals with long QT syndrome. Eur Heart J. 2009 Feb;30(3):330-7. doi: 10.1093/eurheartj/ehn466. Epub 2008 Oct 21.</citation>
    <PMID>18940888</PMID>
  </results_reference>
  <results_reference>
    <citation>Haugaa KH, Amlie JP, Berge KE, Leren TP, Smiseth OA, Edvardsen T. Transmural differences in myocardial contraction in long-QT syndrome: mechanical consequences of ion channel dysfunction. Circulation. 2010 Oct 5;122(14):1355-63. doi: 10.1161/CIRCULATIONAHA.110.960377. Epub 2010 Sep 20.</citation>
    <PMID>20855658</PMID>
  </results_reference>
  <results_reference>
    <citation>ter Bekke RM, Volders PG. Arrhythmogenic mechano-electric heterogeneity in the long-QT syndrome. Prog Biophys Mol Biol. 2012 Oct-Nov;110(2-3):347-58. doi: 10.1016/j.pbiomolbio.2012.07.007. Epub 2012 Jul 24. Review.</citation>
    <PMID>22841828</PMID>
  </results_reference>
  <results_reference>
    <citation>ter Bekke RM, Haugaa KH, van den Wijngaard A, Bos JM, Ackerman MJ, Edvardsen T, Volders PG. Electromechanical window negativity in genotyped long-QT syndrome patients: relation to arrhythmia risk. Eur Heart J. 2015 Jan 14;36(3):179-86. doi: 10.1093/eurheartj/ehu370. Epub 2014 Sep 8.</citation>
    <PMID>25205533</PMID>
  </results_reference>
  <results_reference>
    <citation>Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol. 2000 Mar 1;35(3):778-86.</citation>
    <PMID>10716483</PMID>
  </results_reference>
  <results_reference>
    <citation>Viskin S, Rosso R, Rogowski O, Belhassen B, Levitas A, Wagshal A, Katz A, Fourey D, Zeltser D, Oliva A, Pollevick GD, Antzelevitch C, Rozovski U. Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndrome. Eur Heart J. 2006 Feb;27(4):469-75. Epub 2005 Aug 16.</citation>
    <PMID>16105845</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electromechanical Mapping</keyword>
  <keyword>Risk Stratification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Long QT Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Isoproterenol</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

